Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 09, 2026
TickeronGET DAILY SIGNALS
Alignment Healthcare (ALHC) Drops -43% in 30 Days on Medicare Star Ratings Pressure

Alignment Healthcare (ALHC) Drops -43% in 30 Days on Medicare Star Ratings Pressure

Key Takeaways

  • Alignment Healthcare shares fell approximately 43% in the 30 days through October 9, 2026, sliding from a $13.03 close on September 9 to roughly $7.39.
  • The decline was driven chiefly by a September 15 disclosure at Baird's Global Healthcare Conference and a subsequent CMS Medicare Advantage Star Ratings downgrade on the company's largest contract.
  • The broader trend is even steeper, with shares down roughly 65% from about $21 per share in early July.
  • Key pressures include rising medical costs, a lower 2027 Star Rating on the California H3815 HMO contract, analyst price-target cuts, and investor-rights investigations.
  • Management has reaffirmed its guidance and characterized the issues as near-term "transformation noise" rather than a fundamental deterioration of the business.

Alignment Healthcare (ALHC) Business and Competitive Position

Alignment Healthcare, Inc. operates as a technology-enabled Medicare Advantage insurer serving eligible seniors. It pairs a proprietary data and analytics platform with a high-touch clinical care model that offers HMO, PPO, and special needs plans in California, Arizona, Nevada, North Carolina, and Texas. The approach emphasizes care coordination and population-health management to improve outcomes and manage medical costs. In the Medicare Advantage space it competes with larger players such as UnitedHealth and Humana. I track the stock because of its membership and revenue growth trajectory, progress toward profitability, and the importance of Star Ratings for bonus revenue.

ALHC Stock Performance Over the Past 30 Days and Quarter

From September 9 through October 9, 2026, ALHC moved from a $13.03 close to roughly $7.39, a decline of about 43%. The drop featured two sharp legs lower: one in mid-September and another in early October that took the shares to a new 52-week low. Looking back further, the stock traded near $21 in early July, so the loss over the past three months totals roughly 65% as several negative catalysts overlapped.

Drivers Behind the Recent 30-Day Move

The clearest near-term catalyst arrived on September 15, 2026, when management spoke at Baird's Global Healthcare Conference. Executives noted an additional $10 million to $11 million in planned second-half investments and highlighted medical-cost pressures from hospital billing practices, disputes, appeals, and skilled-nursing-facility trends. The stock fell roughly 20% over the next two sessions on elevated volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

In early October the Centers for Medicare & Medicaid Services released 2027 Star Ratings that lowered the California H3815 HMO contract from 4.0 to 3.5 stars. That contract accounts for more than 75% of membership, and most Medicare Advantage plans need at least 4 stars for bonus payments. The share of enrollment in 4-star-or-better plans fell from about 98% to roughly 24%. JPMorgan cut its price target to $10 from $22 while keeping an Overweight rating. Alignment has disputed the 3.5-star score and plans to pursue administrative remedies and litigation. Separately, law firms including Hagens Berman and Rosen opened investigations citing a whistleblower complaint about expense classification.

Quarterly Context and Broader Pressures

The larger quarterly decline reflects more than one headline. On July 30, 2026, second-quarter revenue missed expectations and guidance implied only about 30% of full-year adjusted EBITDA would come in the second half, sending shares down more than 20% the next day. That reaction was followed by the September conference disclosures and the October Star Ratings update, raising questions about medical-cost trends, reserve adequacy, and the path from growth to profitability. Sector-wide scrutiny on Stars, risk adjustment, and utilization added to the headwinds.

Key Items to Watch Going Forward

Investors will focus on the third-quarter earnings report for any updates to full-year guidance and signs that institutional and hospital cost pressures are moderating. The outcome of planned appeals and litigation over the Star Ratings methodology could affect future bonus revenue. Other areas to monitor include medical-cost trends across Medicare Advantage, the 2028 bid cycle and new-state expansion plans, reserve adequacy for 2025 and 2026 dates of service, and resolution of the pending investor-rights investigations. From what I see, regulatory changes around Stars and risk adjustment remain relevant for the whole sector.

Exploring Tickeron AI Trading Bots

In my own research I have found Tickeron’s AI Trading Bots helpful for testing different strategies across timeframes and market conditions. The platform offers hundreds of bots that trade thousands of tickers, with only the top-performing and most relevant ones featured for review. Traders can examine various approaches before deciding on a single method. For those who want to combine automated signals with their own analysis, the Trending AI Robots page provides a practical starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALHC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for ALHC turns negative, indicating new downward trend

ALHC saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 68 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ALHC turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ALHC entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ALHC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +3.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 247 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (5.743) is slightly higher than the industry average of (3.520). P/E Ratio (36.700) is within average values for comparable stocks, (126.353). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ManagedHealthCare

Industry
N/A
Address
1100 W. Town and Country Road
Phone
+1 844 310-2247
Employees
1849
Web
https://www.alignmenthealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.